Agenus (AGEN) Stock Price

Agenus Price

NASDAQ·CLOSED
7.57
​
Market closed

Revenue has compounded at 30.8% per year over the past 19 years to 114.20 M USD. Agenus's net margin stands at 0.1%, up from -8.1% several years earlier. Analysts set a median price target of 25.00 USD, implying 230.3% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

Agenus stock price

Access this data via the Eulerpool API

Agenus business model & stock analysis

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 328 full-time employees. The company went IPO on 2000-02-04. The firm focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The firm's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The firm's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Frequently asked questions about Agenus

Analysts currently set an average price target of 25.00 USD for the Agenus stock (median: 25.00 USD), implying +230.3 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the Agenus stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Agenus to generate revenue of 124.45 M USD and earnings per share of 0.16 USD.

Converted at the current exchange rate, the Agenus share trades at 6.76 EUR (7.57 USD).

The Agenus share (AGEN) is listed on 5 stock exchanges, including: NASDAQ (AGEN), SIX (Zürich) (AJ81.SW), Frankfurt (AJ81.F), München (AJ81.MU), Düsseldorf (AJ81.DU).

The expected revenue of Agenus is 124.45 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Agenus is 5.74 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Agenus is currently 46.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Agenus stock.

The price-to-sales ratio (P/S) of Agenus is currently 2.15. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Agenus stock.

The Eulerpool Quality Score for Agenus is 4/10.

The ISIN of Agenus is US00847G8042. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Agenus is A1JLKZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Agenus is AGEN. The ticker symbol is used to trade Agenus shares on the stock exchange.

Fair ValueTerminal
6.43 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
1.41 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Feb 4, 2000
ISIN
US00847G8042
Cusip
00847G705
Sedol
B58J3K4
Market capitalization
162.55 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
28.30
P/Ee 2027
-20.67
P/Ee 2028
-21.35
P/Ee 2029
-19.98
P/Ee 2030
-21.85
P/S
P/Se
2.15
EV/EBIT
9.47
P/B Ratio
3.39
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
0.18 %
Last updated Oct 8, 2026, 4:40 PM

Agenus Ticker

DÜSSELDORF · AJ81.DUFRANKFURT · AJ81.FMUNICH · AJ81.MUNASDAQ · AGENSIX · AJ81.SW

All fundamentals and in-depth analysis of Agenus

Our stock analysis for Agenus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agenus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.